EU Seeks to End Medicine Shortages with New Pharmaceutical Strategy
The European Commission has proposed the Critical Medicines Act to strengthen pharmaceutical production within the EU, reduce reliance on external suppliers and prevent future medicine shortages. The initiative marks another step in Europe's broader strategy to build resilience in critical sectors.
After years of recurring shortages of essential medicines, the European Union is taking a strategic step towards reshaping its pharmaceutical policy. The European Commission has unveiled the Critical Medicines Act, a legislative proposal designed to strengthen the production of critical medicines within Europe, reduce dependence on external suppliers, and make healthcare systems more resilient to future crises.
The COVID-19 pandemic exposed one of the European pharmaceutical sector's greatest vulnerabilities: a significant share of active pharmaceutical ingredients and finished medicines is produced outside the EU. Disruptions to global supply chains, geopolitical instability and the concentration of manufacturing in a handful of countries have contributed to shortages of antibiotics, cancer treatments and other essential medicines across the bloc.
The proposed legislation seeks to reverse this trend by supporting strategic manufacturing projects within the European Union. The Commission plans to simplify regulatory procedures, improve investment conditions and encourage the expansion of production capacity for medicines considered vital to public health.
A key pillar of the proposal is a new framework for joint procurement, enabling Member States to coordinate purchases of critical medicines. By pooling demand, governments would be able to negotiate more effectively, secure more reliable supplies and ensure fairer access to essential medicines regardless of the size of national markets. Public procurement would also be used as a strategic tool to promote resilient and diversified supply chains.
The initiative further aims to strengthen international partnerships with trusted allies in order to diversify supplies of pharmaceutical ingredients and reduce dependence on individual producers. While the Commission acknowledges that Europe cannot become entirely self-sufficient, it argues that the bloc must be better prepared for future disruptions by maintaining stronger domestic manufacturing capabilities.
The Critical Medicines Act forms part of the broader reform of the EU's pharmaceutical legislation and reflects Europe's growing emphasis on strategic autonomy. Once largely associated with energy and defence, the concept is now increasingly extending to healthcare and pharmaceuticals. In Brussels, ensuring a stable supply of medicines is no longer viewed solely as a public health issue, but as an essential component of the European Union's economic resilience and security.
Source: European Commision